Clinical Trial Update: Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating erlotinib hydrochloride in patients with muscle-invasive or recurrent urothelial cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureter Cancer
• Urethral Cancer
• Urothelial Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-10